WO2011002721A8 - Modèle mammifère non humain d'un cancer hématopoïétique humain - Google Patents

Modèle mammifère non humain d'un cancer hématopoïétique humain Download PDF

Info

Publication number
WO2011002721A8
WO2011002721A8 PCT/US2010/040221 US2010040221W WO2011002721A8 WO 2011002721 A8 WO2011002721 A8 WO 2011002721A8 US 2010040221 W US2010040221 W US 2010040221W WO 2011002721 A8 WO2011002721 A8 WO 2011002721A8
Authority
WO
WIPO (PCT)
Prior art keywords
human
mammal
methods
cancer
hscs
Prior art date
Application number
PCT/US2010/040221
Other languages
English (en)
Other versions
WO2011002721A1 (fr
Inventor
Ilya B. Leskov
Adam C. Drake
Maroun Khoury
Jianzhu Chen
Christian Pallasch
Michael Hemann
Original Assignee
Leskov Ilya B
Drake Adam C
Maroun Khoury
Jianzhu Chen
Christian Pallasch
Michael Hemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leskov Ilya B, Drake Adam C, Maroun Khoury, Jianzhu Chen, Christian Pallasch, Michael Hemann filed Critical Leskov Ilya B
Priority to PCT/US2010/040221 priority Critical patent/WO2011002721A1/fr
Priority to CN2010800388464A priority patent/CN102762592A/zh
Priority to EP10794608.9A priority patent/EP2448967B1/fr
Priority to DK10794608.9T priority patent/DK2448967T3/en
Priority to SG2011084639A priority patent/SG176117A1/en
Priority to US13/381,307 priority patent/US20120251528A1/en
Priority to JP2012517827A priority patent/JP2012531894A/ja
Priority to SG10201403707QA priority patent/SG10201403707QA/en
Publication of WO2011002721A1 publication Critical patent/WO2011002721A1/fr
Publication of WO2011002721A8 publication Critical patent/WO2011002721A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention a pour objet des composés photolabiles et des procédés d'utilisation des composés. Les composés photolabiles ont un ligand photolibérable, qui peut être biologiquement actif, et qui est photolibéré du composé lors d'une exposition à la lumière. Dans certains modes de réalisation, les composés photolabiles comprennent une antenne lumineuse, telle qu'une molécule marqueur ou un dérivé actif de celle-ci. Dans un mode de réalisation, la lumière est de la lumière visible, qui n'est pas préjudiciable à la viabilité des échantillons biologiques, tels que des cellules et des tissus, dans laquelle la molécule organique libérée est bioactive et peut avoir un effet thérapeutique. Dans un autre mode de réalisation, le ligand photolibérable peut être une molécule marqueur, telle qu'une molécule fluorescente.
PCT/US2010/040221 2009-06-29 2010-06-28 Modèle mammifère non humain d'un cancer hématopoïétique humain WO2011002721A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PCT/US2010/040221 WO2011002721A1 (fr) 2009-06-29 2010-06-28 Modèle mammifère non humain d'un cancer hématopoïétique humain
CN2010800388464A CN102762592A (zh) 2009-06-29 2010-06-28 人类造血细胞癌的非人类哺乳动物模型
EP10794608.9A EP2448967B1 (fr) 2009-06-29 2010-06-28 Modèle mammifère non humain d'un cancer hématopoïétique humain
DK10794608.9T DK2448967T3 (en) 2009-06-29 2010-06-28 NON-HUMAN MAMMALS MODEL OF CANCER human hematopoietic
SG2011084639A SG176117A1 (en) 2009-06-29 2010-06-28 Non-human mammal model of human hematopoietic cancer
US13/381,307 US20120251528A1 (en) 2009-06-29 2010-06-28 Non-Human Mammal Model Of Human Hematopoietic Cancer
JP2012517827A JP2012531894A (ja) 2009-06-29 2010-06-28 ヒト血液癌の非ヒト哺乳動物モデル
SG10201403707QA SG10201403707QA (en) 2009-06-29 2010-06-28 Non-human mammal model of human hematopoietic cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22143809P 2009-06-29 2009-06-29
US61/221,438 2009-06-29
PCT/US2010/040221 WO2011002721A1 (fr) 2009-06-29 2010-06-28 Modèle mammifère non humain d'un cancer hématopoïétique humain

Publications (2)

Publication Number Publication Date
WO2011002721A1 WO2011002721A1 (fr) 2011-01-06
WO2011002721A8 true WO2011002721A8 (fr) 2013-06-13

Family

ID=56080482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/040221 WO2011002721A1 (fr) 2009-06-29 2010-06-28 Modèle mammifère non humain d'un cancer hématopoïétique humain

Country Status (7)

Country Link
US (1) US20120251528A1 (fr)
EP (1) EP2448967B1 (fr)
JP (1) JP2012531894A (fr)
CN (1) CN102762592A (fr)
DK (1) DK2448967T3 (fr)
SG (2) SG10201403707QA (fr)
WO (1) WO2011002721A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002727A1 (fr) * 2009-06-29 2011-01-06 Qingfeng Chen Procédés de production de mammifères non humains humanisés
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
DK3375284T3 (da) 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
EP4193834A1 (fr) * 2012-09-07 2023-06-14 Yale University Animaux non humains génétiquement modifiés et leurs procédés d'utilisation
EP3556206B1 (fr) 2012-11-05 2021-06-02 Regeneron Pharmaceuticals, Inc. Rongeurs génétiquement modifiés et leurs procédés d'utilisation
DK3841877T3 (da) 2014-05-19 2023-11-27 Regeneron Pharma Genetisk modificeret mus, der eksprimerer human EPO
CN104120176A (zh) * 2014-06-10 2014-10-29 杭州艾迪康医学检验中心有限公司 检测cbl基因多态突变位点的引物、方法和试剂盒
JP6752221B2 (ja) 2015-04-13 2020-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｓｉｒｐａ−ｉｌ１５ノックインマウス及びその使用方法
WO2016208532A1 (fr) * 2015-06-22 2016-12-29 全国農業協同組合連合会 Procédé de production d'un animal chimère de sang
EP3332814A4 (fr) * 2015-08-03 2018-07-25 FUJIFILM Corporation Structure de cellule, animal modèle non-humain, procédé de production d'animal modèle non-humain, et procédé d'évaluation d'une substance d'essai
WO2017027578A1 (fr) * 2015-08-13 2017-02-16 Champions Oncology, Inc. Traitement personnalisé de maladies et de troubles
CN112042597B (zh) * 2020-07-22 2022-04-29 南京普恩瑞生物科技有限公司 一种双人源化肿瘤异种移植模型的构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011A (en) * 1850-01-08 Mill foe
US8029A (en) * 1851-04-08 Kellogg
US9015A (en) * 1852-06-15 Manufacture of granular fuel from brush-wood and twigs
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
WO2001072995A2 (fr) * 2000-03-28 2001-10-04 University Of Rochester Methodes de production d"une bibliotheque et methodes de selection de polynucleotides d"interet
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
WO2007044648A2 (fr) * 2005-10-06 2007-04-19 Baylor Research Institute Oncosouris a systeme immun humain
AU2006304392B2 (en) * 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
US20080118477A1 (en) * 2006-11-09 2008-05-22 Rush University Medical Center Umbilical cord mesenchymal stem cells support cord blood hematopoiesis
US20080293661A1 (en) * 2007-05-23 2008-11-27 The General Hospital Corporation Method for treating chronic lymphoid leukemia
WO2009043051A2 (fr) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Molécules se fixant au cd23 et leurs méthodes d'utilisation
WO2010138873A1 (fr) 2009-05-29 2010-12-02 Maroun Khoury Expansion à long terme de cellules souches hématopoïétiques humaines

Also Published As

Publication number Publication date
SG10201403707QA (en) 2014-10-30
DK2448967T3 (en) 2015-07-20
EP2448967A1 (fr) 2012-05-09
WO2011002721A1 (fr) 2011-01-06
EP2448967B1 (fr) 2015-04-15
JP2012531894A (ja) 2012-12-13
CN102762592A (zh) 2012-10-31
EP2448967A4 (fr) 2012-12-05
SG176117A1 (en) 2011-12-29
US20120251528A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
WO2011002721A8 (fr) Modèle mammifère non humain d'un cancer hématopoïétique humain
Cheng et al. Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours
MX2020013293A (es) Guías modificadas de arn para edición génica.
IN2014MN01467A (fr)
IN2014DN06522A (fr)
SG10201902574RA (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
GB2434157A (en) Platelets from stem cells
EP2555627A4 (fr) Méthodes de traitement du cancer
MX342995B (es) Métodos de generar células asesinas naturales.
WO2012094679A3 (fr) Compositions et procédés pour délivrer aux tumeurs des agents se liant à l'oxygène avec une affinité élevée
TR201903889T4 (tr) Korneal endotelyal hücreler üreten yönlendirilmiş diferansiyasyona yönelik yöntem.
NZ587440A (en) Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours
WO2007092196A3 (fr) Compositions et procedes de traitement du syndrome myeloproliferatif
EA201390801A1 (ru) Способ культивирования для получения и поддержания чистой или обогащенной популяции нервных стволовых клеток и/или нервных клеток-предшественников млекопитающего, склонных к дифференцировке с образованием клеток олигодендроцитарной линии in vitro
NZ619576A (en) Compositions and methods for the treatment of infections and tumors
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
MX2023003296A (es) Generacion de lineas de cardiomiocitos auriculares y ventriculares a partir de celulas madre pluripotentes humanas.
WO2012106367A3 (fr) Cellules souches pluripotentes et procédé de stimulation et d'extraction de cellules souches pluripotentes non embryonnaires à partir de cellules provenant du sang d'un animal et utilisation des cellules souches pluripotentes reconstituées pour traiter les maladies telles que la pneumopathie obstructive chronique
MX2022006725A (es) Mejora de célula inmunitaria efectora derivada de ipsc mediante el uso de compuestos pequeños.
WO2014183033A3 (fr) Procede de reparation d'un dysfonctionnement lie a l'age et a une maladie immunitaire et de la senescence cellulaire par des cellules souches lymphoides, puis leur reapplication pour l'utilisation therapeutique
NZ595440A (en) Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
WO2012075462A3 (fr) Méthodes et compositions utilisables en vue du traitement de la dystrophie musculaire progressive
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
SG195128A1 (en) Method of treating the effects of stroke
MX2015008190A (es) Tretaspanina 33 es una candidata para la terapia dirigida de anticuerpos para el tratamiento de linfomas de hodgkin de linfocitos b.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080038846.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10794608

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012517827

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010794608

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13381307

Country of ref document: US